approval
saveSKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
community read0 votes
Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 18, 2026 · 201d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 18, 2026 · 201d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 6, 2026 · 213d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 6, 2026 · 213d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025 · 397d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025 · 397d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025 · 516d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025 · 516d ago
same company · ±60 days · 6
- approvaladalimumab: HUMIRA (ADALIMUMAB) — FDA approvalMar 11, 2020
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalApr 21, 2020
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalApr 21, 2020
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMay 19, 2020
- approvaldivalproex sodium DR: DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvalMay 19, 2020
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMay 19, 2020
comments(0)
5-min edit window · permanent after that